CELG - Celgene Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
102.49
-0.16 (-0.16%)
As of 12:18PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close101.72
Open100.00
Bid102.29 x 100
Ask102.30 x 1300
Day's Range99.99 - 103.23
52 Week Range94.55 - 147.17
Volume6,719,684
Avg. Volume8,293,436
Market Cap80.692B
Beta1.21
PE Ratio (TTM)24.02
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Merger Monday for biotech
    CNBC Videos1 hour ago

    Merger Monday for biotech

    CNBC's Meg Tirrell reports on two major deals in the biotech space: Sanofi buying Bioverativ and Celgene buying Juno Therapeutics.

  • Big pharma on a buying spree as Celgene buys Juno and San...
    CNBC Videos3 hours ago

    Big pharma on a buying spree as Celgene buys Juno and San...

    The "Squawk on the Street" crew discusses Celgene's $9 billion cash deal for Juno Therapeutics and Sanofi's $11.6 billion bid for Massachusetts-based Bioverativ.

  • 2018’s M&A Frenzy Has Begun: Juno Therapeutics Inc, Celgene Corporation
    SmarterAnalyst8 minutes ago

    2018’s M&A Frenzy Has Begun: Juno Therapeutics Inc, Celgene Corporation

    Celgene Corporation (NASDAQ:CELG) announced this morning that it is acquiring Juno Therapeutics Inc (NASDAQ:JUNO) for $9 billion or $87/share (net of the ~10% it already owns). In a report released today, Guggenheim analyst Anthony Butler downgraded JUNO to Hold.

  • TheStreet.com15 minutes ago

    Immunotherapy Stocks Power Higher on Celgene-Juno Deal

    Shares of immunotherapy companies including Ziopharm Oncology and Fate Therapeutics rose early on Monday on the heels of Juno Therapeutics' announced sale to Celgene.

  • The Wall Street Journal33 minutes ago

    [$$] High Prices Won't Deter Biotech Deals

    Expect more expensive biotech acquisitions after two high-priced deals were announced Monday.

  • The Wall Street Journal38 minutes ago

    [$$] Celgene to Buy Juno Therapeutics for $9 Billion

    Celgene said it agreed to buy Juno Therapeutics for $87 a share in cash, or about $9 billion, in a move that will expand Celgene’s portfolio of blood-cancer drugs.

  • TheStreet.com48 minutes ago

    GE Selloff Continues Following BAC Downgrade: LIVE MARKETS BLOG

    Merrill Lynch downgraded GE to 'neutral' from 'buy.'

  • Reuters52 minutes ago

    Celgene to buy Juno for $9 billion to boost cancer pipeline

    Celgene said on Monday it would pay $87 per share for the roughly 90 percent of Juno it does not already own. Juno focuses on chimeric antigen receptor T-cell therapy, known as CAR-T, which harnesses the body's own immune cells to recognize and attack malignant cells.

  • Reuters1 hour ago

    Biotech M&A takes off as Sanofi and Celgene spend $20 billion

    The acquisitions will fuel expectations for a busy year of mergers and acquisitions (M&A) as large drugmakers snap up promising assets from smaller rivals to help revive growth. Sanofi agreed to buy U.S. haemophilia expert Bioverativ for $11.6 billion, its biggest deal for seven years, while Celgene is paying about $9 billion for the 90 percent of cancer specialist Juno Therapeutics it does not already own.

  • Moody's1 hour ago

    Celgene Corporation -- Moody's affirms Celgene at Baa2; stable outlook

    Moody's Investors Service ("Moody's") affirmed the ratings of Celgene Corporation ("Celgene") including the Baa2 senior unsecured long-term rating and the Prime-2 short-term rating. ...

  • Reuters1 hour ago

    Biotech M&A takes off as Sanofi and Celgene spend $20 billion

    The acquisitions will fuel expectations for a busy year of mergers and acquisitions (M&A) as large drugmakers snap up promising assets from smaller rivals to help revive growth. Sanofi agreed to buy U.S. hemophilia expert Bioverativ for $11.6 billion, its biggest deal for seven years, while Celgene is paying about $9 billion for the 90 percent of cancer specialist Juno Therapeutics it does not already own.

  • InvestorPlace1 hour ago

    Why Celgene Corporation Stock Is ALL About the Buyouts

    For the biotech superstar, Celgene Corporation (NASDAQ:CELG), the last few months have not been too kind. CELG stock has hit a rough patch on several different fronts. That included it stopping phase 3 clinical trials for a potential blockbuster for Crohn’s disease as well as reducing forward earnings forecasts based on that stoppage and the fact that Revolve won’t be coming to market.

  • Health-Care Deals Fire Up With Drug Giants Facing Price Pressure
    Bloomberg2 hours ago

    Health-Care Deals Fire Up With Drug Giants Facing Price Pressure

    The new year’s health-care deals began to snowball as Sanofi and Celgene Corp. scooped up assets that promise to offset pricing pressure for some of their top-selling drugs.

  • Juno Therapeutics' Stock Soars on Buyout Confirmation
    Motley Fool2 hours ago

    Juno Therapeutics' Stock Soars on Buyout Confirmation

    The rumor turned out to be true.

  • Stocks edge higher in early trading, led by energy companies
    Associated Press2 hours ago

    Stocks edge higher in early trading, led by energy companies

    NEW YORK (AP) — U.S. stock indexes are edging higher Monday, led by energy companies. High-dividend stocks are also higher as bond yields decline, but industrial companies are falling. Yields had climbed to their highest level in more than three years last week. French pharmaceutical company Sanofi and biotech drugmaker Celgene both announced large acquisitions. Investors aren't fazed by the federal government shutdown as it entered its third day.

  • American City Business Journals2 hours ago

    Celgene diversifies portfolio with purchase of Juno Therapeutics

    Celgene Corp. has agreed to acquire Juno Therapeutics Inc. for about $9 billion, or $87 a share. The announcement comes on the heels of a report that the two companies were finalizing a deal, per The Wall Street Journal . Summit, New Jersey-based Celgene has been trying to diversify its portfolio to help offset losses it would suffer if one of its drugs, Revlimid, loses patent protection in the U.S. This particular deal will add a lymphoma treatment — expected to gain regulatory approval in 2019 — to Celgene’s portfolio.

  • Biotech's $20 Billion Merger Monday Results May Disappoint
    Bloomberg2 hours ago

    Biotech's $20 Billion Merger Monday Results May Disappoint

    Both Celgene and Sanofi seem to have been pressured into iffy deals.

  • Reuters2 hours ago

    US STOCKS-Dow under pressure as industrial stocks weigh

    The S&P and the Nasdaq were marginally higher on Monday, while losses in industrial stocks such as General Electric and Boeing as well as Apple weighed on the Dow. A U.S. government shutdown entered its third day, and a bipartisan group of senators attempted to negotiate a deal just hours before the full Senate planned to vote to restore funding. The Nasdaq Composite was up 19.37 points, or 0.26 percent, at 7,355.75.

  • Celgene Will Buy Juno Therapeutics For $9 Billion; Sanofi Acquires Bioverativ
    Investor's Business Daily3 hours ago

    Celgene Will Buy Juno Therapeutics For $9 Billion; Sanofi Acquires Bioverativ

    Celgene will acquire Juno Therapeutics for $9 billion. Sanofi reached a deal Monday to buy hemophilia drugmaker Bioverativ for $11.6 billion, or $105 a share.

  • Celgene’s $9 Billion Juno Deal Could Be This Year’s Most Expensive
    Bloomberg3 hours ago

    Celgene’s $9 Billion Juno Deal Could Be This Year’s Most Expensive

    Celgene Corp.’s deal to buy Juno Therapeutics Inc. for about $9 billion might not be the biggest deal that we’ll see this year. It could be the most expensive.

  • Barrons.com3 hours ago

    Morning Movers: Juno Soars on Celgene Takeout; GE Slumps on Merrill Cut

    S&P 500 futures have dipped 0.1%, while Dow Jones Industrial Average futures have fallen 49 points, or 0.2%. Nasdaq Composite futures are little changed. Contrast that with Europe, where Germany's Social Democrats agreed to negotiate with Angela Merkel on a new government, something that could pave the way for her to serve a fourth term as that country's leader.

  • Reuters3 hours ago

    US STOCKS-Wall St on track to open lower as U.S. shutdown enters third day

    Wall Street was set to start the week slightly lower as a U.S. government shutdown entered its third day, while investors assessed a flurry of multi-billion corporate mergers. The Senate is set to vote at midday on Monday, following failed attempts by Democrats and Republicans to strike a deal on Sunday to fund government operations.

  • Benzinga3 hours ago

    The Market In 5 Minutes: Celgene Buys Juno, Netflix Earnings Preview, Eagles And Patriots Advance To Super Bowl

    IN THE NEWS Netflix (NASDAQ: NFLX ) added more than 5 million users during the third quarter, which was stronger than expected and has investors hopeful the momentum carried over into the fourth quarter. ...

  • Will These 4 Large-Cap Drug Stocks Be Big Winners This Earnings Season?
    Zacks4 hours ago

    Will These 4 Large-Cap Drug Stocks Be Big Winners This Earnings Season?

    Here is a look at four large-cap pharma and biotech stocks including Merck (MRK) that could surpass earnings expectations in the fourth quarter.

  • TheStreet.com4 hours ago

    Celgene Makes $9 Billion Cancer Treatment Play for Juno Therapeutics

    Celgene inks the Summit, N.J.-based group's biggest-ever takeover with a $9 billion play for cancer treatment specialist biotech Juno Therapeutics.